Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHXMYU)

Drug Name

LY3361237 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Sjogren syndrome	4A43.20	Phase 2	[1]
Systemic lupus erythematosus	4A40.0	Phase 2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B- and T-lymphocyte attenuator (BTLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JS004	DMFMWLQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B- and T-lymphocyte attenuator (BTLA)	TTER58P	BTLA_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05781451) A Phase 2, Open Label Study of Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05123586) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.
3	Clinical pipeline report, company report or official report of Junshi Biosciences.